{"id":"NCT00518531","sponsor":"Amgen","briefTitle":"Denosumab Adherence Preference Satisfaction Study","officialTitle":"A Multicenter, Randomized, Cross-Over, Open-label Study to Evaluate the Adherence, Preference, and Satisfaction of Denosumab and Alendronate in Postmenopausal Women With Low Bone Mineral Density","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09-01","primaryCompletion":"2009-06-01","completion":"2010-06-01","firstPosted":"2007-08-20","resultsPosted":"2014-01-07","lastUpdate":"2019-12-03"},"enrollment":250,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Osteoporosis"],"interventions":[{"type":"DRUG","name":"alendronate","otherNames":[]},{"type":"DRUG","name":"denosumab","otherNames":[]}],"arms":[{"label":"Treatment Sequence B","type":"OTHER"},{"label":"Treatment Sequence A","type":"OTHER"}],"summary":"The primary objective is to evaluate the adherence of subjects to subcutaneous (SC) 60 mg denosumab every 6 months (Q6M) treatment compared to oral 70 mg alendronate once a week (QW) treatment at the end of treatment period 1 (12 months).","primaryOutcome":{"measure":"Adherence With Treatment in the First Treatment Period","timeFrame":"Treatment period 1 (Month 1 to Month 12)","effectByArm":[{"arm":"Alendronate","deltaMin":95,"sd":null},{"arm":"Denosumab","deltaMin":111,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0259"}]},"eligibility":{"minAge":"55 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":12},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["21927922","23676636","20827547","31665314"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":118},"commonTop":["Arthralgia","Pain in extremity","Back pain","Headache","Cough"]}}